Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Where is myeloma I-O moving?

Saad Usmani • 13 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies CAR-T Checkpoint inhibitors Pembrolizumab

Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, talks on where he believes the myeloma immuno-oncology (I-O) space is moving. Specifically, Dr Usmani mentions bispecific antibodies, checkpoint inhibition, and CAR-T cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Saad Usmani

1:14
Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myeloma
Saad Usmani • 8 Sep 2023
1:53
MajesTEC‐1 update: rates of infection in patients with myeloma receiving teclistamab
Saad Usmani • 8 Sep 2023
1:43
High-risk multiple myeloma: addressing challenges and unmet needs
Saad Usmani • 8 Sep 2023
2:05
Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma
Saad Usmani • 25 Aug 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals